he Drugs for Neglected Diseases initiative (DNDi) is a patient-needs driven, not-for-profit research and development (R&D) organization that develops safe, effective, and affordable medicines for the millions of neglected patients across the world. DNDi focuses on developing new treatments for the most neglected patients suffering from diseases such as human African trypanosomiasis (sleeping sickness), leishmaniasis, Chagas disease, filariasis, paediatric HIV, mycetoma, and hepatitis C. The initiative’s primary objective is to deliver a total of 16 to 18 treatments by 2023 and to establish a strong R&D portfolio for these diseases.
4 VISION, MISSION & STRATEGY R&D MODEL & PORTFOLIO 14
STRENGTHENING EXISTING CAPACITIES
ADVOCACY, COMMUNICATIONS & FUNDRAISING
62 FINANCIAL REPORT
Cover photo: A mobile team of the National Control Programme for sleeping sickness screens a young boy for sleeping sickness, in Mpata village, Democratic Republic of the Congo.
DNDi Annual Report 2015 › 3